Works matching IS 17562856 AND DT 2016 AND VI 9 AND IP 6
Results: 5
Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2016, v. 9, n. 6, p. 474, doi. 10.1177/1756285616665564
- By:
- Publication type:
- Article
Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2016, v. 9, n. 6, p. 462, doi. 10.1177/1756285616664300
- By:
- Publication type:
- Article
Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2016, v. 9, n. 6, p. 454, doi. 10.1177/1756285616661929
- By:
- Publication type:
- Article
Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2016, v. 9, n. 6, p. 445, doi. 10.1177/1756285616661115
- By:
- Publication type:
- Article
An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2016, v. 9, n. 6, p. 483, doi. 10.1177/1756285616656296
- By:
- Publication type:
- Article